MedTrace Logo

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

NCT06508775 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-11-26

No results posted yet for this study

Summary

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Conditions

  • Melanoma Stage III
  • B-cell Non Hodgkin Lymphoma
  • Pediatric ALL
  • Childhood Non-Hodgkin Lymphoma
  • Acute Lymphatic Leukemia
  • Chronic Lymphatic Leukemia
  • Melanoma Stage IV

Interventions

BIOLOGICAL

MB-CART19.1

Assessment of long-term safety and efficacy of MB-CART19.1 treatment.

BIOLOGICAL

MB-CART20.1

Assessment of long-term safety and efficacy of MB-CART20.1 treatment.

BIOLOGICAL

MB-CART2019.1

Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.

Sponsors & Collaborators

  • Miltenyi Biomedicine GmbH

    lead INDUSTRY

Principal Investigators

  • Claudia Rössig, Prof. Dr. · Universitätsklinikum Münster

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-05
Primary Completion
2040-12-31
Completion
2040-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06508775 on ClinicalTrials.gov